OR WAIT null SECS
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
January 15, 2024
Boehringer Ingelheim is investing €120 million (US$131 million) into its Koropi, Greece site to expand production for new therapeutics.
January 12, 2024
Webinar Date/Time: Wed, Feb 7, 2024 10:30 AM CET (4:30 AM EST)
January 11, 2024
Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.
January 10, 2024
Cherwell Laboratories’ cleanroom microbiology solutions will join AnalytiChem’s group of seven companies across Europe, North America, and Australia.
January 08, 2024
Webinar Date/Time: Thu, Jan 25, 2024 11:00 AM EST
Webinar Date/Time: Tue, Jan 30, 2024 11:00 AM EST
January 04, 2024
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
January 03, 2024
Revolutionary therapies restructure pharmaceutical manufacturing.
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
There are positive indications for future growth.